Exclusive Summary

• Possesses dual highest-tier GMP certifications from US-FDA and PIC/S, enabling low-barrier, fast-track market entry into Western block and over 50 PIC/S member countries globally.
• Deeply anchored as a WHO Essential Medicine and robust first-line guideline therapy globally, serving hundreds of millions of patients demanding reliable chronic gynecological and HRT treatments.
• Leveraging China's manufacturing edge and economies of scale, the pure Distribution cooperation model grants overseas partners substantially broader margin capabilities compared to originator or Western-made equivalents.
• Acting as a classic off-patent generic molecule, its strict compliance parameters and formidable supply stability exactly address ongoing essential drug shortages and massive national bulk-procurement tenders internationally.